Bayer's Stroke Medication Achieves Trial Objectives; Analyst Anticipates Favorable Data from Bristol Myers' Milvexian Following Unsuccessful Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Source: Benzinga
Bayer's Phase 3 Study Results: Bayer AG announced positive topline results from the Phase 3 OCEANIC-STROKE study for its oral FXIa inhibitor asundexian, which significantly reduced the risk of ischemic stroke without increasing major bleeding risks compared to placebo.
Impact on Bristol-Myers Squibb: The positive results for asundexian are seen as beneficial for Bristol-Myers Squibb's milvexian program, especially after the recent halt of the LIBREXIA-ACS trial due to lack of efficacy.
Dosing Concerns: Analysts are questioning whether the dosing levels of milvexian being tested are optimal, particularly in light of Bayer's previous findings that indicated insufficient dosing of asundexian in a different study.
Market Reaction: Following the news, Bristol-Myers Squibb's stock rose by 4.57%, reflecting investor optimism regarding the implications of Bayer's trial results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 58.030
Low
37.00
Averages
55.86
High
68.00
Current: 58.030
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
China's Pharma Sector Unaffected by Regulatory Scrutiny
- Industry Growth Outlook: JW Therapeutics CEO Leo Tian stated that despite Beijing's tightening scrutiny over sensitive technology deals, China's pharmaceutical sector remains robust, with biotech licensing deals expected to reach new heights, indicating strong demand for China-developed experimental medicines.
- Reliance on International Collaboration: JW Therapeutics continues to thrive in cross-border collaborations, particularly in cell and gene therapies, with Tian emphasizing that the company has not felt any impact from regulatory changes, showcasing its stability and adaptability in the international market.
- Investor Confidence Challenges: While JW Therapeutics operates normally, China's blocking of Meta's acquisition of Manus may heighten risks for global investors looking to invest in advanced tech firms with ties to the country, potentially affecting future investment decisions.
- Exploring Cooperation Opportunities: JW is actively seeking collaborations with companies outside China, particularly within its product pipeline, reflecting the company's strategic intent to expand in the global market.
See More
Bristol Myers Squibb Shares Rebound but Risks Remain
- Patent Cliff Risk: Bristol Myers Squibb faces a daunting patent cliff, with sales of its blood cancer drug Revlimid sharply declining due to generic competition, while its top-selling drugs Eliquis and Opdivo will lose U.S. patent exclusivity in 2028, potentially leading to significant future revenue declines.
- Acquisition Integration Challenges: The company acquired Mirati Therapeutics, Karuna Therapeutics, and RayzeBio in 2023, and while these acquisitions may enhance growth prospects, they also introduce integration and clinical risks that could impact short-term financial performance.
- Growth vs. Legacy Drug Conflict: Although Bristol Myers Squibb emphasized in its 2026 Q1 earnings report that its growth portfolio constitutes the majority of total revenue, legacy drugs still account for approximately 46% of revenue, and with total revenue increasing by only 1% on a constant-currency basis, there is a risk that new drugs may not offset losses from older blockbusters.
- Investor Risk Appetite: For risk-averse investors, Bristol Myers Squibb may not be an ideal choice, while patient long-term investors might find the 4.2% dividend yield appealing, indicating that the stock could still be attractive under certain investment styles.
See More
Bristol Myers Squibb Faces Daunting Patent Cliff
- Patent Cliff Risks: Bristol Myers Squibb's blood cancer drug Revlimid is experiencing a sharp decline in sales due to generic competition, and its two top-selling products, Eliquis and Opdivo, are set to lose U.S. patent exclusivity by 2028, posing significant revenue challenges ahead.
- Limited Growth Potential: Although the company has made acquisitions of Mirati Therapeutics, Karuna Therapeutics, and RayzeBio in 2023 to enhance growth prospects, its legacy drugs still account for approximately 46% of total revenue, with overall revenue growth stagnating at just 1%, indicating that new drugs may not offset losses from older blockbusters.
- Diverging Investor Sentiment: Risk-averse investors may find Bristol Myers Squibb's stock unattractive, while patient investors could be drawn to its 4.2% dividend yield, despite the company's fortunes not expected to improve significantly in the short term.
- Poor Market Performance: Despite a rebound of about 11% after a decline, Bristol Myers Squibb's shares remain below their early March peak, with a forward P/E ratio of only 9.4 suggesting potential undervaluation, but investors should remain cautious of integration and clinical risks.
See More
BMY Shares Snap Six-Day Gain with Minor Decline
- Stock Decline: Bristol-Myers Squibb (BMY) saw a minor decline of 0.15% on Friday, closing at $59.46 after six consecutive days of gains, indicating short-term market volatility.
- Analyst Ratings: Seeking Alpha's Quant Rating gives BMY a Hold rating of 3.37, with an A+ for profitability but a D- for growth, reflecting market caution regarding its future growth prospects.
- Analyst Opinions: Among 29 analysts, 10 rated BMY as a Buy, 18 as Hold, and 1 as Strong Sell, indicating a divergence in market sentiment, particularly as the company faces a major patent cliff.
- Future Catalysts: Analyst Joseph Minton highlighted that BMY's robust pipeline and CAR-T optionality position it for potential re-rating opportunities in 2026, with forward P/E ratios possibly reaching 10-11x, showcasing long-term investment value.
See More
Bristol Myers Squibb Showcases New Drug Research Results
- Successful Clinical Trials: Bristol Myers Squibb presented late-breaking results from the Phase 3 SUCCESSOR-2 trial of mezigdomide at the 2026 ASCO Annual Meeting, demonstrating its efficacy in relapsed or refractory multiple myeloma patients, potentially introducing a new treatment option in this area.
- Diverse Drug Pipeline: The company will also showcase various candidates including pumitamig, iza-bren, iberdomide, and golcadomide, highlighting their potential across different tumor types, thereby reinforcing its leadership position in oncology therapeutics.
- Innovative Treatment Combinations: During the meeting, Bristol Myers Squibb will emphasize innovative treatment combinations across multiple tumor types, aiming to provide meaningful options for cancer patients and enhancing the company's competitive edge in a crowded market.
- Global Collaborative Research: Collaboration with BioNTech will present the first global data for a PD-1 or PD-(L)1 x VEGF bispecific immunomodulator in previously untreated non-small cell lung cancer, further expanding the company's research impact on a global scale.
See More
Bristol Myers Squibb's Stock Lacks Confidence Despite Strong Fundamentals
- Valuation Advantage: Bristol Myers Squibb's stock trades at approximately 10 times forward earnings, making it the cheapest among its 11 peers in the S&P 500, reflecting low market confidence in its future growth prospects.
- Attractive Dividend Yield: With only 8% stock returns so far this year, the dividend yield has surpassed 4%, second only to Pfizer in the pharmaceutical sector, appealing to income-seeking investors.
- Rapid Growth of New Products: In Q1 2026, Bristol Myers Squibb generated $11.5 billion in revenue, a 3% year-over-year increase, with its growth portfolio rising 12%, demonstrating resilience against patent expiration risks.
- Cost Control Measures: The company anticipates achieving approximately $2 billion in annual cost savings by 2027 through restructuring and productivity initiatives, further enhancing its financial health and market competitiveness.
See More
China's Pharma Sector Unaffected by Regulatory Scrutiny
- Industry Growth Outlook: JW Therapeutics CEO Leo Tian stated that despite Beijing's tightening scrutiny over sensitive technology deals, China's pharmaceutical sector remains robust, with biotech licensing deals expected to reach new heights, indicating strong demand for China-developed experimental medicines.
- Reliance on International Collaboration: JW Therapeutics continues to thrive in cross-border collaborations, particularly in cell and gene therapies, with Tian emphasizing that the company has not felt any impact from regulatory changes, showcasing its stability and adaptability in the international market.
- Investor Confidence Challenges: While JW Therapeutics operates normally, China's blocking of Meta's acquisition of Manus may heighten risks for global investors looking to invest in advanced tech firms with ties to the country, potentially affecting future investment decisions.
- Exploring Cooperation Opportunities: JW is actively seeking collaborations with companies outside China, particularly within its product pipeline, reflecting the company's strategic intent to expand in the global market.
See More
Bristol Myers Squibb Shares Rebound but Risks Remain
- Patent Cliff Risk: Bristol Myers Squibb faces a daunting patent cliff, with sales of its blood cancer drug Revlimid sharply declining due to generic competition, while its top-selling drugs Eliquis and Opdivo will lose U.S. patent exclusivity in 2028, potentially leading to significant future revenue declines.
- Acquisition Integration Challenges: The company acquired Mirati Therapeutics, Karuna Therapeutics, and RayzeBio in 2023, and while these acquisitions may enhance growth prospects, they also introduce integration and clinical risks that could impact short-term financial performance.
- Growth vs. Legacy Drug Conflict: Although Bristol Myers Squibb emphasized in its 2026 Q1 earnings report that its growth portfolio constitutes the majority of total revenue, legacy drugs still account for approximately 46% of revenue, and with total revenue increasing by only 1% on a constant-currency basis, there is a risk that new drugs may not offset losses from older blockbusters.
- Investor Risk Appetite: For risk-averse investors, Bristol Myers Squibb may not be an ideal choice, while patient long-term investors might find the 4.2% dividend yield appealing, indicating that the stock could still be attractive under certain investment styles.
See More
Bristol Myers Squibb Faces Daunting Patent Cliff
- Patent Cliff Risks: Bristol Myers Squibb's blood cancer drug Revlimid is experiencing a sharp decline in sales due to generic competition, and its two top-selling products, Eliquis and Opdivo, are set to lose U.S. patent exclusivity by 2028, posing significant revenue challenges ahead.
- Limited Growth Potential: Although the company has made acquisitions of Mirati Therapeutics, Karuna Therapeutics, and RayzeBio in 2023 to enhance growth prospects, its legacy drugs still account for approximately 46% of total revenue, with overall revenue growth stagnating at just 1%, indicating that new drugs may not offset losses from older blockbusters.
- Diverging Investor Sentiment: Risk-averse investors may find Bristol Myers Squibb's stock unattractive, while patient investors could be drawn to its 4.2% dividend yield, despite the company's fortunes not expected to improve significantly in the short term.
- Poor Market Performance: Despite a rebound of about 11% after a decline, Bristol Myers Squibb's shares remain below their early March peak, with a forward P/E ratio of only 9.4 suggesting potential undervaluation, but investors should remain cautious of integration and clinical risks.
See More
BMY Shares Snap Six-Day Gain with Minor Decline
- Stock Decline: Bristol-Myers Squibb (BMY) saw a minor decline of 0.15% on Friday, closing at $59.46 after six consecutive days of gains, indicating short-term market volatility.
- Analyst Ratings: Seeking Alpha's Quant Rating gives BMY a Hold rating of 3.37, with an A+ for profitability but a D- for growth, reflecting market caution regarding its future growth prospects.
- Analyst Opinions: Among 29 analysts, 10 rated BMY as a Buy, 18 as Hold, and 1 as Strong Sell, indicating a divergence in market sentiment, particularly as the company faces a major patent cliff.
- Future Catalysts: Analyst Joseph Minton highlighted that BMY's robust pipeline and CAR-T optionality position it for potential re-rating opportunities in 2026, with forward P/E ratios possibly reaching 10-11x, showcasing long-term investment value.
See More
Bristol Myers Squibb Showcases New Drug Research Results
- Successful Clinical Trials: Bristol Myers Squibb presented late-breaking results from the Phase 3 SUCCESSOR-2 trial of mezigdomide at the 2026 ASCO Annual Meeting, demonstrating its efficacy in relapsed or refractory multiple myeloma patients, potentially introducing a new treatment option in this area.
- Diverse Drug Pipeline: The company will also showcase various candidates including pumitamig, iza-bren, iberdomide, and golcadomide, highlighting their potential across different tumor types, thereby reinforcing its leadership position in oncology therapeutics.
- Innovative Treatment Combinations: During the meeting, Bristol Myers Squibb will emphasize innovative treatment combinations across multiple tumor types, aiming to provide meaningful options for cancer patients and enhancing the company's competitive edge in a crowded market.
- Global Collaborative Research: Collaboration with BioNTech will present the first global data for a PD-1 or PD-(L)1 x VEGF bispecific immunomodulator in previously untreated non-small cell lung cancer, further expanding the company's research impact on a global scale.
See More
Bristol Myers Squibb's Stock Lacks Confidence Despite Strong Fundamentals
- Valuation Advantage: Bristol Myers Squibb's stock trades at approximately 10 times forward earnings, making it the cheapest among its 11 peers in the S&P 500, reflecting low market confidence in its future growth prospects.
- Attractive Dividend Yield: With only 8% stock returns so far this year, the dividend yield has surpassed 4%, second only to Pfizer in the pharmaceutical sector, appealing to income-seeking investors.
- Rapid Growth of New Products: In Q1 2026, Bristol Myers Squibb generated $11.5 billion in revenue, a 3% year-over-year increase, with its growth portfolio rising 12%, demonstrating resilience against patent expiration risks.
- Cost Control Measures: The company anticipates achieving approximately $2 billion in annual cost savings by 2027 through restructuring and productivity initiatives, further enhancing its financial health and market competitiveness.
See More
